Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
Jia Liu, Ruiyuan Cao, Mingyue Xu, Xi Wang, Huanyu Zhang, Hengrui Hu, Yufeng Li, Zhihong Hu, Wu Zhong, Manli Wang, Jia Liu, Ruiyuan Cao, Mingyue Xu, Xi Wang, Huanyu Zhang, Hengrui Hu, Yufeng Li, Zhihong Hu, Wu Zhong, Manli Wang
No abstract availableKeywords: Autophagy; Transcription.
Conflict of interest statement
Conflict of interestThe authors declare that they have no conflict of interest.
Figures
References
- Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.
- Holshue ML, et al. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2001191.
- Weniger H. Review of side effects and toxicity of chloroquine. Bull. World Health. 1979;79:906.
- McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 1983;75:11–18. doi: 10.1016/0002-9343(83)91265-2.
- Mauthe M, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14:1435–1455. doi: 10.1080/15548627.2018.1474314.
- Savarino A, et al. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 2006;6:67–69. doi: 10.1016/S1473-3099(06)70361-9.
- Mingo RM, et al. Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J. Virol. 2015;89:2931–2943. doi: 10.1128/JVI.03398-14.
- Zheng N, Zhang X, Rosania GR. Effect of phospholipidosis on the cellular pharmacokinetics of chloroquine. J. Pharmacol. Exp. Ther. 2011;336:661–671. doi: 10.1124/jpet.110.175679.
- Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl Acad. Sci. USA. 1978;75:3327–3331. doi: 10.1073/pnas.75.7.3327.
- Popert AJ. Choloroquine: a review. Rheumatology. 1976;15:235–238. doi: 10.1093/rheumatology/15.3.235.
- Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand. J. rheumatol. 1974;3:103–108. doi: 10.3109/03009747409115809.
- Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
Source: PubMed